Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$40.41 USD
-1.16 (-2.79%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $40.42 +0.01 (0.02%) 4:22 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Price, Consensus and EPS Surprise
AMPH 40.41 -1.16(-2.79%)
Will AMPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMPH
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Implied Volatility Surging for Amphastar (AMPH) Stock Options
Other News for AMPH
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Verona Pharma (VRNA) and Henry Schein (HSIC)
Piper Sandler Keeps Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
Amphastar management to meet with Piper Sandler